PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Medicxi Announces €500 Million Fund V Medicxi
17-Nov-2025 Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic Captain T Cell
13-Nov-2025 Cliniphai and Nested Knowledge Announce Partnership at ISPOR Europe 2025 to Accelerate Global Health Technology Assessment (HTA) Dossier Localization with AI Cliniphai
13-Nov-2025 Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers Matisse Pharmaceuticals
13-Nov-2025 Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference Tiziana Life Sciences
12-Nov-2025 Integrated DNA Technologies and Beckman Coulter Life Sciences Partner to Advance Cancer Research Through Automated NGS Workflows Integrated DNA Technologies
12-Nov-2025 Mark Egerton Appointed Chairman of Panthera Biopartners Panthera Biopartners
12-Nov-2025 EpiCypher Launches Fiber-seq Kit to Democratize Single-Molecule Chromatin Mapping EpiCypher
12-Nov-2025 AC Immune to Present at the Jefferies 2025 London Healthcare Conference AC Immune
11-Nov-2025 MadeAi™ Unveils New Capabilities for GVD and JCA Reporting, Setting a New Benchmark for Life Science GenAI-Enabled Evidence Synthesis and Reporting MadeAi
11-Nov-2025 Pangaea Data’s AI platform adopted by University of Illinois Cancer Center to help clinicians uncover social drivers of health critical for patient care Pangaea Data
11-Nov-2025 OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel OGT
10-Nov-2025 Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers Nouscom